Synairgen PLC (AIM:SNG, OTC:SYGGF) said it is making strides in preparing for further clinical trials of SNG001 as a broad-spectrum antiviral based on insights gained from the Covid pandemic.
The company aims to identify patients most likely to benefit from the treatment, focusing on those with high virus levels or weak immune responses.
This targeted approach could lead to more efficient and cost-effective trials.
"We hope to maximise the benefits of treatment with SNG001 by targeting patients most likely to respond to treatment by applying both existing and new technologies for patient selection in our next trials of SNG001," said chief executive Richard Marsden.
"This will enable us to focus on the most appropriate patients which will ultimately lead to trials of SNG001 in more targeted, but still large, patient populations at high risk of severe outcomes."
Synairgen reported a loss of £5.5 million for the first half of 2023, reflecting its heavy investment in R&D. More importantly, it ended the period to 30 June with £16 million in the bank.